Physician influence on medication adherence, evidence from a population-based cohort

• Published in: PloS one Vol. 17; no. 12; p. e0278470
• Main Authors: Yao, Shenzhen, Lix, Lisa M, Teare, Gary, Evans, Charity, Blackburn, David F
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.12.2022; Public Library of Science (PLoS)
• Subjects: Cohort Studies; Dosage and administration; Earth Sciences; Evaluation; General Practitioners; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Medication Adherence; Medicine and Health Sciences; Methods; Middle Aged; Patient compliance; People and Places; Physicians (General practice); Prescription writing; Retrospective Studies; Saskatchewan; Services; Statins; Saskatchewan; Canada
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0278470

The overall impact of physician prescribers on population-level adherence rates are unknown. We aimed to quantify the influence of general practitioner (GP) physician prescribers on the outcome of optimal statin medication adherence. We conducted a retrospective cohort study using health administrative databases from Saskatchewan, Canada. Participants included physician prescribers and their patients beginning a new statin medication between January 1, 2012 and December 31, 2017. We grouped prescribers based on the prevalence of optimal adherence (i.e., proportion of days covered ≥ 80%) within their patient group. Also, we constructed multivariable logistic regression analyses on optimal statin adherence using two-level non-linear mixed-effects models containing patient and prescriber-level characteristics. An intraclass correlation coefficient was used to estimate the physician effect. We identified 1,562 GPs prescribing to 51,874 new statin users. The median percentage of optimal statin adherence across GPs was 52.4% (inter-quartile range: 35.7% to 65.5%). GP prescribers with the highest patient adherence (versus the lowest) had patients who were older (median age 61.0 vs 55.0, p<0.0001) and sicker (prior hospitalization 39.4% vs 16.4%, p<0.001). After accounting for patient-level factors, only 6.4% of the observed variance in optimal adherence between patients could be attributed to GP prescribers (p<0.001). The majority of GP prescriber influence (5.2% out of 6.4%) was attributed to the variance unexplained by patient and prescriber variables. The overall impact of GP prescribers on statin adherence appears to be very limited. Even "high-performing" physicians face significant levels of sub-optimal adherence among their patients.